A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant.
Chem Commun (Camb)
; 57(4): 504-507, 2021 Jan 14.
Article
en En
| MEDLINE
| ID: mdl-33331360
ABSTRACT
A novel STING agonist, CDGSF, ipsilaterally modified with phosphorothioate and fluorine, was synthesized. The phosphorothioate in CDGSF might be a site for covalent conjugation. Injection of CDGSF generated an immunogenic ("hot") tumor microenvironment to suppress melanoma, more efficiently than dithio CDG. In particular, immunization with SARS-CoV-2 spike protein using CDGSF as an adjuvant elicited an exceptionally high antibody titer and a robust T cell response, overcoming the drawbacks of aluminum hydroxide. These results highlighted the therapeutic potential of CDGSF for cancer immunotherapy and the adjuvant potential of the STING agonist in the SARS-CoV-2 vaccine for the first time.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
2_ODS3
/
4_TD
/
6_ODS3_enfermedades_notrasmisibles
Problema de salud:
2_enfermedades_transmissibles
/
4_covid_19
/
4_pneumonia
/
6_malignant_skin_melanoma
/
6_other_respiratory_diseases
/
6_skin_diseases
Asunto principal:
Neoplasias Cutáneas
/
Melanoma Experimental
/
Adyuvantes Inmunológicos
/
Vacunas contra la COVID-19
/
COVID-19
/
Proteínas de la Membrana
/
Nucleótidos Cíclicos
Idioma:
En
Revista:
Chem Commun (Camb)
Asunto de la revista:
QUIMICA
Año:
2021
Tipo del documento:
Article